Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. on September 12, 2022. The report discloses a presentation made by senior management at the H.C. Wainwright 24th Annual Global Investment Conference on the same date.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document serves solely to disclose the availability of a corporate presentation and does not contain audited or unaudited financial statements.
Material Changes
No material changes to financial performance or operations are reported within the text of this filing. The report is limited to the disclosure of the presentation materials furnished as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing explicitly states that the information contained in Item 7.01 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and is not subject to the liabilities under such section. Consequently, the presentation shall not be deemed incorporated by reference into any other filings. No specific guidance, outlook, or risk factors are detailed in the body of this 8-K.
Key Facts for Investor Verification
- Verify the content of the corporate presentation (Exhibit 99.1) for any forward-looking statements or strategic updates, as the 8-K text itself contains no operational details.
- Note that the presentation materials are not legally "filed" and are not incorporated by reference into other SEC documents.
- Confirm the leadership status, as the report was signed by James Martin, who holds the titles of Chief Financial Officer and Co-Interim Chief Executive Officer.
- Check the Nasdaq Capital Market listing status for the common stock trading under the symbol COCP.